Jaguar Health says all pediatric MVID patients enter single-blind extension in crofelemer pivotal trial - JAGX News | RalliesJaguar Health says all pediatric MVID patients enter single-blind extension in crofelemer pivotal trial
J
JAGX• Pediatric MVID patients move into trial extension
- Jaguar Health moved all randomized pediatric MVID patients into a single-blind extension of its pivotal crofelemer crossover trial.
- Extension treatment will generate longer-term safety and efficacy support for an NDA filing targeted for mid-2027.
- Prior results were already presented at ESPGHAN 2026, indicating sustained reductions in parenteral support needs with long-term oral crofelemer.
- An independent monitoring committee reviewed the double-blind phase safety profile, clearing continued active treatment during the extension.
•
